Antimycotic activity of Bacillus subtilis 534 strain: the bases of the probiotic sporobacterin


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To investigate the antimycotic activity of the probiotic strain Bacillus subtilis 534 in the in vitro cultivation conditions. Materials and methods. The taxonomic identification of the isolated pathogenic fungi and their antimycotic sensitivity/resistance determined on an automated MicroScan WalkAway-96 plus System. The strain B. subtilis 534 was grown under submerged cultivation conditions. The antimycotic activity of the culture liquid was determined by the agar diffusion assay. Thirty-six clinical isolates of the pathogenic fungi Candida albicans, C. catenulata, C. glabrata, C. krusei, C. lusitaniae, C. parapsilosis, С. tropicalis, Cryptococcus neoformans, and Trichosporon spp. and the algae Prototheca spp. were used as tests for the determination of their antimycotic activity. Results. The clinical isolates differ in resistance/sensitivity to the antimycotics amphotericin, miconazole, ketoconazole, itraconazole, and fluconazole, whereas 10 isolates are resistant to all five of these drugs. Thirty-four out of the 36 clinical isolates are sensitive to the culture liquid of the strain B. subtilis 534 and to its isolated active components. Presumably, strain 534 in the human intestine also forms antimicrobial compounds that are active against pathogenic fungi, which is responsible for its antimycotic efficacy. Conclusion. The long-term medical application of the probiotic sporobacterin that is B. subtilis 534 spore suspension suggests that the latter is effective and free of side effects.

Full Text

Restricted Access

About the authors

N. I Gabrielyan

Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Ministry of Health of Russia

Email: labgso@mail.ru
MD, Head, Department of Endotoxicosis and Pyoseptic Complications Moscow, Russia

I. V Drabkina

Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Ministry of Health of Russia

Email: drabkina58@mail.ru
Bacteriologist Moscow, Russia

T. V Krupenio

Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Ministry of Health of Russia

Email: ypsa89@mail.ru
Laboratory Researcher Moscow, Russia

M. V Demyankova

Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Ministry of Health of Russia; G.F. Gauze Research Institute for Search for New Antibiotics

Email: mary_bunny@mail.ru
Laboratory Researcher Moscow, Russia

I. A Malanicheva

G.F. Gauze Research Institute for Search for New Antibiotics

Email: malanicheva.irina@yandex.ru
Cand. Biol. Sci., Senior Researcher Moscow, Russia

B. F Vasilyeva

G.F. Gauze Research Institute for Search for New Antibiotics

Email: bfvas@yandex.ru
Researcher Moscow, Russia

T. A Efimenko

G.F. Gauze Research Institute for Search for New Antibiotics

Email: efimen@inbox.ru
Researcher Moscow, Russia

I. G Sumarukova

G.F. Gauze Research Institute for Search for New Antibiotics

Email: noks59@yandex.ru
Researcher Moscow, Russia

A. A Glukhova

G.F. Gauze Research Institute for Search for New Antibiotics

Email: alglukhova@yandex.ru
Researcher Moscow, Russia

Yu. V Boykova

G.F. Gauze Research Institute for Search for New Antibiotics

Email: boykowa.yulya@yandex.ru
Researcher Moscow, Russia

N. D Malkina

G.F. Gauze Research Institute for Search for New Antibiotics

Email: utvar@blagoslovenie.su
Cand. Biol. Sci., Researcher Moscow, Russia

V. V Udalova

G.F. Gauze Research Institute for Search for New Antibiotics

Email: viudalova@yandex.ru
Researcher Moscow, Russia

V. A Alferova

G.F. Gauze Research Institute for Search for New Antibiotics

Email: alferovava@gmail.com
Researcher Moscow, Russia

V. A Korshun

G.F. Gauze Research Institute for Search for New Antibiotics

Email: korshun@yandex.ru
ChemD, Head, Laboratory Chemical Study of Biologically Active Compounds of Microbial Origin Moscow, Russia

O. V Efremenkova

G.F. Gauze Research Institute for Search for New Antibiotics

Email: ovefr@yandex.ru
Cand. Biol. Sci., Head, Sector for Searching for Natural Compounds that Overcome Bacterial Resistance, Department of Microbiology 11, Bolshaya Pirogovskaya St., Build. 1, Moscow119021, Russia Telephone: +7(499) 255-77-31

References

  1. World Health Organization. Antimicrobial resistance. 2016. URL: http://www.who.int/mediacentre/factsheets/fs194/en/
  2. Butler M.S., Blaskovich M.A., Cooper M.A. Antibiotics in the clinical pipeline in 2013. J.Antibiot. 2013; 66(10): 571-91.
  3. Butler M.S., Blaskovich M.A., Cooper M.A. Antibiotics in the clinical pipeline at the end of 2015. J. Antibiot. 2017; 70(1): 3-24.
  4. Похиленко В.Д., Перелыгин В.В. Пробиотики на основе спорообразующих бактерий и их безопасность. Химическая и биологическая безопасность 2007; 32-33(2-3): 20-41.
  5. Скрыпник И.Н., Маслова А.С. Современные спорообразующие пробиотики в клинической практике. Сучасна гастроентерологія 2009; 3(47): 81-90.
  6. Савустьяненко А.В. Механизмы действия пробиотиков на основе Bacillus subtilis. Актуальная инфектология 2016; 2(11): 35-44.
  7. Sanders M.E., Morelli L., Tompkins T.A. Sporeformers as Human Probiotics: Bacillus, Sporolactobacillus, and Brevibacillus. Comprehensive reviews in food science and food safety 2003; 2(3): 101-10. doi: 10.1111/j.1541-4337.2003. tb00017.
  8. Cutting S.M. Bacillus probiotics. Food Microbiol. 2011; 28: 214e220. doi: 10.1016/j.fm.2010.03.007.
  9. Sorokulova I. Modern Status and Perspectives of Bacillus Bacteria as Probiotics J. Prob. Health. 2013; 1(4): e106.
  10. Никитенко В.И., Полякова B.C., Никитенко М.В. Препарат споробактерин. Новые данные о механизме действия этого и других живых бактериальных препаратов. Научный вестник Тюменской медицинской академии 2001; (2): 70-2.
  11. Габриэлян Н.И., Давыдов Д.С., Горская Е.М. Использование споробактерина в послеоперационном периоде у пациентов кардиохирургического профиля. Антагонизм in vitro споробактерина в отношении нозокомиальных штаммов бактерий. Вестн. трансплантол. и искусств. органов 2008; (6): 12-8.
  12. Габриэлян Н.И., Горская Е.М., Крупенио Т.В., Зенкова В.А., Ефименко Т.А., Маланичева И.А., Сумарукова И.Г., Ефременкова О.В., Евлашкина В.Ф., Давыдов Д.С. Оценка антимикробной активности бациллярного пробиотика Bacillus subtilis (штамм 534). Эпидемиол. инфекц болезни. Актуал. вопр. 2016; (1): 41-7.
  13. Ефременкова О.В., Габриэлян Н.И., Маланичева И.А., Ефименко Т.А., Терехова Л.П., Удалова В.В., Глухова А.А., Рогожин Е.А., Алферова В.А., Коршун В.А., Кубанова М.Х., Драбкина И.В., Крупенио Т.В. Антибиотическая активность пробиотического штамма Bacillus subtilis 534 в отношении клинических изолятов Acinetobacter baumannii. Антибиотики и химиотерапия 2016; 61(9-10): 3-7.
  14. Осипова И.Г., Сорокулова И.Б., Васильева Е.А., Буданова Е.В. Доклинические испытания новых споровых пробиотиков. Вестн. РАМН 2005; (12): 36-40.
  15. Leser T.D., Knarreborg A., Worm J. Germination and outgrowth of Bacillus subtilis and Bacillus licheniformis spores in the gastrointestinal tract of pigs. J. Appl. Microbiol. 2008; 104(4): 1025-33.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies